Bliss GVS Pharma · NSE: BLISSGVS · BSE: 506197
Q1 FY22 results · Apr–Jun 2021
Bliss GVS Pharma reported revenue from operations of ₹168.15 crore (up 29.8% from Q1 FY21) and net profit of ₹26.13 crore (up 56.9% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 168.15 | 129.55 | +29.8% | 132.05 | +27.3% |
| Other income | 7.82 | 7.04 | +11.0% | 6.33 | +23.6% |
| Total income | 175.96 | 136.59 | +28.8% | 138.38 | +27.2% |
| Profit before tax | 36.69 | 20.40 | +79.8% | 16.58 | +121.2% |
| Net profit for the period | 26.13 | 16.65 | +56.9% | 8.15 | +220.5% |
| Attributable to shareholders of the company | 24.25 | 16.19 | +49.8% | 6.24 | +288.6% |
| EPS, basic (₹) | 2.35 | 1.57 | +49.7% | 0.61 | +285.2% |
| Net margin (%) | 15.5 | 12.9 | 6.2 |
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 133.03 | 114.02 | +16.7% | 105.23 | +26.4% |
| Other income | 7.90 | 6.95 | +13.6% | 4.30 | +83.7% |
| Total income | 140.93 | 120.97 | +16.5% | 109.53 | +28.7% |
| Profit before tax | 29.04 | 20.41 | +42.3% | 14.07 | +106.4% |
| Net profit for the period | 21.66 | 17.10 | +26.7% | 9.16 | +136.4% |
| EPS, basic (₹) | 2.10 | 1.66 | +26.5% | 0.89 | +136.0% |
| Net margin (%) | 16.3 | 15.0 | 8.7 |
Consolidated
- Filed with BSE
- 31 Jul 2021, 18:42 IST
- Board meeting
- 31 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jul 2021, 18:42 IST
- Board meeting
- 31 Jul 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE